Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Completed · Phase 2 · Has a placebo group

Conditions studied: Dyslipidemias, High Cholesterol, Hypercholesterolemia

In brief

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.

Key facts

Study ID
NCT04753606
Run by
NewAmsterdam Pharma
People needed
120
Starts
2021-02-18
Expected to finish
2021-08-30
Last updated by the study team
2024-07-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.